427 related articles for article (PubMed ID: 8562503)
1. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
2. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M.
Honey K; Forbush K; Jensen PE; Rudensky AY
J Immunol; 2004 Apr; 172(7):4142-50. PubMed ID: 15034026
[TBL] [Abstract][Full Text] [Related]
3. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of the reactions between the invariant chain (85-99) peptide and proteins of the murine class II MHC.
Liang MN; Beeson C; Mason K; McConnell HM
Int Immunol; 1995 Sep; 7(9):1397-404. PubMed ID: 7495747
[TBL] [Abstract][Full Text] [Related]
5. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
6. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
7. Evidence that binding site occupancy is necessary and sufficient for effective major histocompatibility complex (MHC) class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP).
Zhong G; Castellino F; Romagnoli P; Germain RN
J Exp Med; 1996 Nov; 184(5):2061-6. PubMed ID: 8920896
[TBL] [Abstract][Full Text] [Related]
8. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
9. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II.
Sette A; Southwood S; Miller J; Appella E
J Exp Med; 1995 Feb; 181(2):677-83. PubMed ID: 7836921
[TBL] [Abstract][Full Text] [Related]
10. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
Kropshofer H; Vogt AB; Hämmerling GJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
[TBL] [Abstract][Full Text] [Related]
11. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules.
Adams S; Humphreys RE
Eur J Immunol; 1995 Jun; 25(6):1693-702. PubMed ID: 7614997
[TBL] [Abstract][Full Text] [Related]
12. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
13. Self-release of CLIP in peptide loading of HLA-DR molecules.
Kropshofer H; Vogt AB; Stern LJ; Hämmerling GJ
Science; 1995 Nov; 270(5240):1357-9. PubMed ID: 7481823
[TBL] [Abstract][Full Text] [Related]
14. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
Fujii S; Senju S; Chen YZ; Ando M; Matsushita S; Nishimura Y
Hum Immunol; 1998 Oct; 59(10):607-14. PubMed ID: 9757942
[TBL] [Abstract][Full Text] [Related]
15. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
16. pH-dependent peptide binding properties of the type I diabetes-associated I-Ag7 molecule: rapid release of CLIP at an endosomal pH.
Hausmann DH; Yu B; Hausmann S; Wucherpfennig KW
J Exp Med; 1999 Jun; 189(11):1723-34. PubMed ID: 10359576
[TBL] [Abstract][Full Text] [Related]
17. A continuous central motif of invariant chain peptides, CLIP, is essential for binding to various I-A MHC class II molecules.
Weenink SM; Milburn PJ; Gautam AM
Int Immunol; 1997 Feb; 9(2):317-25. PubMed ID: 9040013
[TBL] [Abstract][Full Text] [Related]
18. The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules.
Wu S; Gorski J
Mol Immunol; 1996; 33(4-5):371-7. PubMed ID: 8676888
[TBL] [Abstract][Full Text] [Related]
19. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
Stumptner P; Benaroch P
EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
[TBL] [Abstract][Full Text] [Related]
20. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
Hitzel C; Koch N
Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
